• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Fennec Pharmaceuticals Inc.

    11/12/24 7:38:18 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FENC alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    FENNEC PHARMACEUTICALS INC.

     

    Common Shares

    (Title of Class of Securities)

     

    31447P100

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 31447P100

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      DG Capital Management, LLC
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ☐
      (b) ☒
       
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware, USA

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
      1,522,204*
       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
      1,522,204*
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      1,522,204*
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      ☐
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      5.5%*
       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      IA

     

     
     

     

    CUSIP No. 31447P100

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      DG Value Partners II Master Fund, LP
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ☐
      (b) ☒
       
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
      1,314,903*
       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
      1,314,903*
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      1,314,903*
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      4.8%*
       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      PN

     

     
     

     

    CUSIP No. 31447P100

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Dov Gertzulin
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a) ☐
      (b) ☒
       
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      United States

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
      1,522,204*
       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
      1,522,204*
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      1,522,204*
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      5.5%*
       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      IN, HC

     

     
     

     

    CUSIP No. 31447P100

     

    Item 1. (a). Name of Issuer:
         
        Fennec Pharmaceuticals Inc. (the “Issuer”)
         
      (b). Address of issuer’s principal executive offices:
         
       

    PO Box 13628, 68 TW Alexander Drive

    Research Triangle Park, NC 27709

         
    Item 2. (a). Name of person filing:
         
        DG Capital Management, LLC*
        DG Value Partners II Master Fund, LP*
        Dov Gertzulin*
         
      (b). Address or principal business office or, if none, residence:
         
        460 Park Avenue, 22nd Floor
        New York, NY 10022
         
      (c). Citizenship:
         
        DG Capital Management, LLC – Delaware, USA
        DG Value Partners II Master Fund, LP – Cayman Islands
        Dov Gertzulin – United States
         
      (d). Title of class of securities:
         
        Common Shares
         
      (e). CUSIP No.: 31447P100

     

     
     

     

    CUSIP No. 31447P100

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:
       
      N/A
       
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
        DG Capital Management, LLC: 1,522,204*
        DG Value Partners II Master Fund, LP: 1,314,903*
        Dov Gertzulin– 1,522,204*
         
      (b) Percent of class:
         
        DG Capital Management, LLC: 5.5%*
        DG Value Partners II Master Fund, LP: 4.8%*
        Dov Gertzulin: 5.5%*
         
      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote
         
        DG Capital Management, LLC: 0
        DG Value Partners II Master Fund, LP: 0
        Dov Gertzulin: 0
         
      (ii) Shared power to vote or to direct the vote
         
        DG Capital Management, LLC: 1,522,204*
        DG Value Partners II Master Fund, LP: 1,314,903*
        Dov Gertzulin – 1,522,204*
         
      (iii) Sole power to dispose or to direct the disposition of
         
        DG Capital Management, LLC: 0
        DG Value Partners II Master Fund, LP: 0
        Dov Gertzulin: 0
         
      (iv) Shared power to dispose or to direct the disposition of
         
        DG Capital Management, LLC: 1,522,204*
        DG Value Partners II Master Fund, LP: 1,314,903*
        Dov Gertzulin – 1,522,204*

     

    *The Common Shares (the “Shares”) reported herein are held by private investment funds, including DG Value Partners II Master Fund, LP, and separately managed accounts (the “DG Entities”) for which DG Capital Management, LLC serves as the investment manager. Dov Gertzulin serves as the managing member of DG Capital Management, LLC. By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the DG Entities.

     

    The percentages reported herein are based on a total of 27,432,234 Shares outstanding, based on information in the Form 10-Q most recently filed by the Issuer on November 8, 2024.

     

    This report shall not be deemed an admission that any reporting person herein or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person’s pecuniary interest therein, if any.

     

     
     

     

    CUSIP No. 31447P100

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
       

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      N/A

     

       
    Item 7. If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    CUSIP No. 31447P100

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 12, 2024 DG Capital Management, LLC
         
      By: /s/ Dov Gertzulin
        Dov Gertzulin, Managing Member
         
      DG Value Partners II Master Fund, LP
         
      By: /s/ Dov Gertzulin
        Dov Gertzulin, Managing Member of the General Partner, DG Capital Partners II, LLC
         
      Dov Gertzulin
         
      By: /s/ Dov Gertzulin
        Dov Gertzulin, Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

     

    CUSIP No. 31447P100

     

    Exhibit 1

     

    Joint Filing Statement

     

    Statement Pursuant to Rule 13d-1(k)(1)

     

    The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Shares of Fennec Pharmaceuticals Inc., together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

     

    This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.

     

    Dated: November 12, 2024 DG Capital Management, LLC
         
      By: /s/ Dov Gertzulin
        Dov Gertzulin, Managing Member
         
      DG Value Partners II Master Fund, LP
         
      By: /s/ Dov Gertzulin
        Dov Gertzulin, Managing Member of the General Partner, DG Capital Partners II, LLC
         
      Dov Gertzulin
         
      By: /s/ Dov Gertzulin
        Dov Gertzulin, Individually

     

     

     

    Get the next $FENC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FENC

    DatePrice TargetRatingAnalyst
    11/22/2022$9.00 → $12.00Neutral → Overweight
    Cantor Fitzgerald
    9/7/2022$11.00Overweight
    CapitalOne
    8/8/2022$14.00Buy
    Craig Hallum
    More analyst ratings

    $FENC
    Financials

    Live finance-specific insights

    See more
    • Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update. "In the first quarter, we sharpened our strategic focus and achieved sustainable gro

      5/13/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 13, 2025Time:8:30 a.m. ETWebcast Link:https://edge.media-server.com/mmc/p/nb5vbq6oParticipant Link:https://register-conf.media-server.com/register/BIbc2eaa3f157d4c6891b71246a83bdb02 To access the li

      5/8/25 4:17:00 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company's Convertible Debt Facility ~ ~ Continued Momentum in the Adolescent and Young Adult (AYA) Segment and Academic Setting Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ PEDMARQSI® Now Commercially Available to Patients and Healthcare Providers in the United Kingdom and Germany ~ ~ Japan Clini

      3/10/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PEDMARK issued to FENNEC PHARMACEUTICALS INC

      Submission status for FENNEC PHARMACEUTICALS INC's drug PEDMARK (ORIG-1) with active ingredient SODIUM THIOSULFATE has changed to 'Approval' on 09/20/2022. Application Category: NDA, Application Number: 212937, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/20/22 3:54:04 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Leadership Updates

    Live Leadership Updates

    See more
    • Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

      ~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success in the expansion of PEDMARK® use in c

      8/5/24 6:26:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Fennec Pharmaceuticals upgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald upgraded Fennec Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

      11/22/22 9:21:25 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CapitalOne initiated coverage on Fennec Pharmaceuticals with a new price target

      CapitalOne initiated coverage of Fennec Pharmaceuticals with a rating of Overweight and set a new price target of $11.00

      9/7/22 8:58:27 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Craig Hallum resumed coverage on Fennec Pharmaceuticals with a new price target

      Craig Hallum resumed coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $14.00

      8/8/22 8:53:55 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Hackman Jeffrey S. bought $104,602 worth of shares (15,000 units at $6.97) (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      5/19/25 5:42:21 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Andrade Robert bought 12,500 shares, increasing direct ownership by 14% to 104,271 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      4/3/24 5:00:11 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raykov Rosty bought 29,167 shares, increasing direct ownership by 10% to 316,638 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      4/3/24 4:55:10 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Fennec Pharmaceuticals Inc.

      10-Q - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

      5/14/25 4:10:12 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Fennec Pharmaceuticals Inc.

      DEF 14A - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

      4/25/25 4:25:31 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Fennec Pharmaceuticals Inc.

      10-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

      3/26/25 4:34:57 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Andrade Robert exercised 8,220 shares at a strike of $5.10, increasing direct ownership by 5% to 158,520 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      5/23/25 4:20:06 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Hackman Jeffrey S. bought $104,602 worth of shares (15,000 units at $6.97) (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      5/19/25 5:42:21 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF FINANCIAL OFFICER Andrade Robert was granted 16,667 shares, increasing direct ownership by 12% to 150,300 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      5/19/25 4:30:32 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Fennec Pharmaceuticals Inc.

      SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

      11/12/24 7:38:18 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

      SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

      6/27/24 4:43:33 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

      SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

      2/14/24 10:47:17 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update. "In the first quarter, we sharpened our strategic focus and achieved sustainable gro

      5/13/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 13, 2025Time:8:30 a.m. ETWebcast Link:https://edge.media-server.com/mmc/p/nb5vbq6oParticipant Link:https://register-conf.media-server.com/register/BIbc2eaa3f157d4c6891b71246a83bdb02 To access the li

      5/8/25 4:17:00 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company's Convertible Debt Facility ~ ~ Continued Momentum in the Adolescent and Young Adult (AYA) Segment and Academic Setting Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ PEDMARQSI® Now Commercially Available to Patients and Healthcare Providers in the United Kingdom and Germany ~ ~ Japan Clini

      3/10/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care